During this fireside we welcome Unicycive Therapeutics. Unicycive (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

This Fireside Chat was recorded during the Lytham Partners Fall 2024 Investor Conference.